R&D | November 21, 2025
Lilly expands biotech footprint with new Gateway Labs in Philadelphia
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
New Chesterbrook office strengthens customer engagement, partner collaboration, and regional expansion strategy
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
